Search the Newsreel

Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients

Wellington Management Group LLP and related entities have disclosed a 5.12% beneficial ownership stake in Cytokinetics, Incorporated (CYTK) for their clients, as detailed in an Amendment No. 2 to a Schedule 13G filing. This holding, totaling 7,116,724 shares, is managed by various Wellington investment …

CYTK Maintained by Barclays -- Price Target Raised to $110

Barclays has maintained an Overweight rating for Cytokinetics (CYTK) and increased its price target to $110, reflecting a positive outlook despite the company being unprofitable. The stock is considered undervalued by 60.9% according to GF Value™, but its GF Score™ of 51/100 indicates average …

Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb

Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment that it does not infringe on U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company also seeks an injunction to prevent infringement litigation related to its …

Form 8K Cytokinetics Inc For: 13 August By Investing.com

This article from Investing.com reports that Cytokinetics Inc. filed a Form 8K on August 13th. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of …

Barclays raises Cytokinetics stock price target on strong Myqorzo sales

Barclays has increased its price target for Cytokinetics (NASDAQ: CYTK) shares to $110 from $95, maintaining an Overweight rating. This upgrade follows strong second-quarter Myqorzo sales of $25.3 million, significantly beating consensus estimates. The drug's successful launch and prescription growth, alongside the company's better-than-expected …

Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK

Handelsbanken Fonder AB increased its stake in Cytokinetics, Incorporated by 63.8% in the second quarter, now owning 405,000 shares worth $34.5 million. This comes as other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts have largely maintained a "Moderate Buy" …

Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cytokinetics Inc (CYTK), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 22 analysts, the stock has a strong buy recommendation with an average target price of $79.00 and an upside space …

Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK

Dimensional Fund Advisors LP significantly increased its stake in Cytokinetics, Incorporated, acquiring an additional 75.2% of shares, totaling 94,503 shares valued at $6.23 million. Other institutional investors also raised their positions, reflecting broadly positive sentiment despite recent insider selling and a year-over-year revenue decline. …

Cytokinetics president & CEO Robert Blum sells $575,700 in shares

Robert I. Blum, President and CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of common stock for $575,700, while also acquiring 7,500 shares through option exercise for $79,500. Following these transactions, Blum directly holds 377,820 shares, with additional indirect holdings. This comes as CYTOKINETICS …

Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $575,700.00 in Stock

Cytokinetics CEO Robert Blum sold 7,500 shares of the company's stock for $575,700, reducing his direct holdings by 1.95%. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts generally maintain a "Moderate Buy" rating for CYTK with …

Cytokinetics, Incorporated Revenue Breakdown – NASDAQ:CYTK

Cytokinetics, Incorporated (NASDAQ: CYTK) generated $88.04 million USD in revenue last year, primarily from its Muscle Activators and Muscle Inhibitors segment. This represents a significant increase from the previous year's $18.47 million USD. The United States was the greatest contributor to this revenue.

CYTOKINETICS, INCORPORATED : LEERINK PARTNERS RAISES TARGET PRICE TO $103 FROM $100

LEERINK PARTNERS has increased its target price for CYTOKINETICS, INCORPORATED (CYTK.O) from $100 to $103. The article is a brief financial news update from Reuters, indicating a positive analyst sentiment towards the company. It notes that the content reflects only the author's opinion and …

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cytokinetics, Incorporated (NASDAQ:CYTK) on behalf of investors who purchased securities before December 27, 2023. The investigation seeks to determine if the company or its officers engaged in corporate wrongdoing. The law firm is encouraging …

Cytokinetics (NASDAQ:CYTK) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Cytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval

Cytokinetics (CYTK) stock has shown strong returns over five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. Despite recent UK approval for MYQORZO, the stock's high price-to-book ratio is not a reliable indicator due to the company's development-heavy …

Wall Street Zen Downgrades Cytokinetics (NASDAQ:CYTK) to Sell

Wall Street Zen downgraded Cytokinetics (NASDAQ:CYTK) to a "sell" rating from "hold," despite the broader analyst consensus remaining a "Moderate Buy." This downgrade follows the biopharmaceutical company's quarterly results, which saw revenue decline 57.1% year-over-year and substantial losses, although reported revenue and EPS still …

Citizens raises Cytokinetics stock price target on strong launch

Citizens has raised its price target for Cytokinetics (NASDAQ:CYTK) to $110 from $105, maintaining a Market Outperform rating, citing the strong launch of MYQORZO and ongoing pipeline development. The company's stock has surged 131% over the past year, currently trading at $81.37, and its …

Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses

Cytokinetics (CYTK) saw its shares fall 6% despite early success with its new cardiomyopathy drug, MYQORZO, which generated $25.3 million in net product revenue. The company posted a significant net loss of $198.8 million in Q2 2026, widening from the previous year, as heavy …

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …

Cytokinetics (NASDAQ:CYTK) Shares Down 6.6% - Here's What Happened

Cytokinetics (NASDAQ:CYTK) shares fell 6.6% despite reporting Q2 2026 revenues and EPS that beat analyst expectations. The stock decline was influenced by a significant year-over-year revenue decrease, widening losses, substantial operating cash outflow, and ongoing insider selling. Despite these concerns, Wall Street analysts maintain …

Cytokinetics, Incorporated Stock 12‑Month Price Target Cut to $107.65, Implies 32% Upside

Cytokinetics, Incorporated's average 12-month stock price target has been slightly cut from $108.47 to $107.65 by 20 analysts, still implying a 32% potential upside from its August 6 closing price. The consensus rating remains a "Buy" across 23 covering analysts, with 21 buys and …

CYTOKINETICS INC Q2 2026: Revenue $28.6M, EPS $(1.50) — 10-Q Summary

CYTOKINETICS INC (CYTK) reported Q2 2026 results with revenue of $28.6 million, primarily driven by the first commercial sales of MYQORZO, which generated $25.3 million. The company posted a net loss of $198.8 million and diluted EPS of $(1.50), both wider than the previous …

Needham & Company LLC Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock

Needham & Company LLC raised its price target for Cytokinetics (NASDAQ:CYTK) from $102 to $112, maintaining a "buy" rating and indicating a potential upside of 41.92%. This positive outlook is supported by a "Moderate Buy" consensus from analysts, with the company also exceeding quarterly …

How Investors May Respond To Cytokinetics (CYTK) UK MYQORZO Approval Amid Wider Quarterly Loss

Cytokinetics (CYTK) recently reported a wider net loss in Q2 2026, with revenue decreasing year-over-year. Despite this, the company's cardiac myosin inhibitor, MYQORZO, received UK marketing authorization, offering a potential catalyst for growth. The article discusses how this approval and early MYQORZO uptake could …

Cytokinetics (CYTK) Releases Q2 2026 Earnings: Revenue Beats but Losses Persist

Cytokinetics Q2 2026 Earnings Call Transcript

Cytokinetics reported strong Q2 2026 earnings, driven by better-than-expected MYQORZO launch momentum, with $25.3 million in net product revenue and increased prescriber adoption. The company also announced positive Phase III trial results for aficamten in non-obstructive HCM, planning a supplemental NDA submission in Q4 …

Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch

Cytokinetics (NASDAQ:CYTK) exceeded Q2 2026 estimates, reporting a narrower-than-expected loss and product revenue significantly above forecasts, driven by the successful launch of its cardiac drug MYQORZO. Despite the strong financial performance, the company's shares remained unchanged in after-market trading, suggesting the positive results were …

Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q2 Revenue $28.6M, vs. FactSet Est of $17.6M

Cytokinetics, Incorporated (CYTK) reported its Q2 revenue at $28.6 million, significantly surpassing FactSet's estimate of $17.6 million. The article also mentions recent insider stock sales and regulatory approvals for its heart disease drugs, MYQORZO (Aficamten) and omecamtiv mecarbil. The company specializes in developing muscle …

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cytokinetics (Nasdaq: CYTK) reported strong second-quarter 2026 financial results, including $25 million in MYQORZO net product revenue and approximately $1.7 billion in cash, cash equivalents, and investments. The company highlighted significant progress in the commercial launch of MYQORZO for obstructive hypertrophic cardiomyopathy (oHCM), with …

[10-Q] CYTOKINETICS INC Quarterly Earnings Report

Cytokinetics (CYTK) Earnings Date and Reports 2026 $CYTK

Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to a loss of $1.12 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

How Cytokinetics Incorporated (CYTK) Affects Rotational Strategy Timing

The article analyzes Cytokinetics Incorporated (CYTK) using AI models, revealing divergent sentiment across various time horizons and suggesting choppy market conditions. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to optimize position sizing and manage risk for …